Highlights
- Dual inhibition of Ang-2 and VEGF-A with faricimab results in more rapid anatomical drying compared to VEGF inhibition alone during the loading phase of nAMD treatment.
- Post hoc analysis of the TENAYA and LUCERNE trials identifies fluid resolution (IRF and SRF) by week 12 as a robust predictor of the ability to maintain extended dosing intervals (Q12W or Q16W) at two years.
- Patients achieving early fluid resolution were nearly twice as likely (OR 1.76 to 1.99) to achieve the maximum 16-week dosing interval compared to those with persistent fluid at week 12.
- These findings support a ‘fast-start’ clinical strategy where early anatomical response guides long-term management and reduces the injection burden for patients with nAMD.
Background
Neovascular age-related macular degeneration (nAMD) remains a leading cause of vision loss worldwide. While the introduction of vascular endothelial growth factor (VEGF) inhibitors revolutionized the management of this disease, the high treatment burden associated with frequent intravitreal injections remains a significant barrier to optimal real-world outcomes. Many patients in clinical practice experience ‘treatment fatigue,’ leading to under-dosing and subsequent vision loss.
Faricimab, the first bispecific antibody designed for intraocular use, targets two distinct pathways involved in vascular instability: VEGF-A and angiopoietin-2 (Ang-2). While VEGF-A drives angiogenesis and vascular permeability, Ang-2 promotes vascular leakage and inflammation by antagonizing the Tie2 receptor. By inhibiting both, faricimab aims to stabilize the retinal vasculature more effectively than anti-VEGF monotherapy. The pivotal TENAYA and LUCERNE trials established the non-inferiority of faricimab compared to aflibercept, with the majority of patients extending to 12- or 16-week dosing intervals. However, a critical clinical question remained: Can we predict which patients will achieve this high level of durability early in the treatment course?
Key Content
The TENAYA and LUCERNE Clinical Framework
The TENAYA (NCT03823287) and LUCERNE (NCT03823300) studies were randomized, double-masked, multicenter phase 3 trials. They compared faricimab 6 mg (up to every 16 weeks [Q16W]) with aflibercept 2 mg (every 8 weeks [Q8W]). The primary endpoint was the change in best-corrected visual acuity (BCVA) at week 48, which demonstrated that faricimab was non-inferior to aflibercept while allowing for significantly longer treatment intervals. By week 112, approximately 80% of faricimab-treated patients were on dosing intervals of 12 weeks or more.
Rapid Fluid Resolution as a Clinical Marker
Initial head-to-head dosing analyses during the first 12 weeks (the loading phase) showed that faricimab-treated eyes achieved a ‘fluid-free’ state faster than those treated with aflibercept 2 mg. This prompted a deeper investigation into whether this early anatomical success was merely a short-term benefit or a harbinger of long-term durability. Intraretinal fluid (IRF) and subretinal fluid (SRF) are the primary indicators of disease activity in nAMD, and their persistence is often linked to poorer visual outcomes and the need for more frequent injections.
Post Hoc Analysis: Linking Week 12 to Week 112
A specific post hoc analysis (Pitcher et al., 2026) utilized data from 552 participants in the faricimab arms of TENAYA and LUCERNE. The researchers categorized patients based on whether they achieved complete resolution of IRF and SRF through week 12 (after the first three monthly doses). Using multinomial logistic regression, they tested the association between this early response and the dosing intervals at week 20/24 (the first extension opportunity) and week 112 (study exit).
The results were statistically significant and clinically illuminating:
- At Week 20/24: Participants with IRF/SRF resolution by week 12 were significantly more likely to qualify for Q16W dosing (OR 1.99; 95% CI, 1.23-3.21; P = .005) or Q12W dosing (OR 1.77; 95% CI, 1.09-2.87; P = .02) compared to those who still had fluid.
- At Week 112: The predictive power of the week 12 response persisted. Those who dried early were more likely to be on a Q16W regimen at the end of two years (OR 1.76; 95% CI, 1.10-2.83; P = .02).
Mechanistic Insights into Dual Inhibition
The superior drying and durability of faricimab are attributed to its unique mechanism of action. In a healthy retinal vasculature, Ang-1 binds to the Tie2 receptor to maintain vessel stability. In nAMD, Ang-2 levels are elevated, competing with Ang-1 and leading to ‘vascular plasticization’—a state where vessels are more prone to leak and proliferate in response to VEGF. By neutralizing Ang-2, faricimab restores Tie2 signaling, which enhances vascular stability and reduces the sensitivity of the vessels to VEGF, potentially explaining why the anatomical effect is both more rapid and more durable than VEGF inhibition alone.
Expert Commentary
The findings from the Pitcher et al. analysis provide a practical roadmap for retinal specialists. In the past, the initial response to anti-VEGF therapy was often viewed as a measure of short-term efficacy. These data suggest that the first 12 weeks of faricimab therapy represent a ‘window of prediction.’ If a patient’s retina dries completely within this window, the clinician can have high confidence in successfully extending the treatment interval to 12 or 16 weeks, thereby significantly reducing the patient’s treatment burden over the subsequent two years.
However, it is important to note the limitations. This was a post hoc analysis, meaning the trials were not originally powered specifically to test this association. Additionally, while the odds ratios are impressive, they do not imply that patients who do not dry by week 12 cannot eventually reach extended intervals; rather, they may require more intensive management initially to achieve stability. The ‘real-world’ application of these findings will also depend on individual patient factors, such as the presence of pigment epithelial detachments (PEDs) or specific genetic predispositions, which may influence fluid dynamics independently of the drug mechanism.
Conclusion
The paradigm of nAMD treatment is shifting from merely maintaining vision to maximizing durability without compromising anatomical outcomes. The evidence from the TENAYA and LUCERNE trials indicates that faricimab’s dual Ang-2/VEGF-A inhibition offers a distinct advantage in rapid fluid resolution. The clear association between early drying (week 12) and long-term durability (week 112) suggests that early anatomical response is a valid biomarker for treatment extension. Future research should focus on whether aggressive early treatment in ‘slow responders’ can eventually shift them toward the high-durability cohorts observed in this study.
References
- Pitcher JD, Koh AHC, Tan CS, et al. Rapid Fluid Resolution and Durability With Faricimab in Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2026;144(3):269-272. PMID: 41712218.
- Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of faricimab in neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, multicentre, phase 3 non-inferiority trials. Lancet. 2022;399(10326):729-740. PMID: 35085502.
- Sahni J, Dugel PU, Pollack JS, et al. Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: 2-Year Results from the Phase 3 TENAYA and LUCERNE Trials. Ophthalmology. 2024;131(2):189-202. PMID: 37633516.
